Part of the data from this study was presented at the 18th World Congress for Bronchology and Interventional Pulmonology, Kyoto, Japan, April 13--17, 2014.

Introduction {#tca12301-sec-0001}
============

Conventional transbronchial needle aspiration (TBNA) is a useful procedure for hilar‐mediastinal diagnosis and staging. Needle size varies from 19--22 gauge. The size of a needle can influence the result and larger gauge needles can obtain satisfactory sample volumes with higher diagnostic yield.[1](#tca12301-bib-0001){ref-type="ref"}, [2](#tca12301-bib-0002){ref-type="ref"} To obtain cytology specimens, 20--22 gauge needles are usually used, whereas 19‐gauge needles are needed to obtain a core of tissue for histologic diagnosis.[2](#tca12301-bib-0002){ref-type="ref"}, [3](#tca12301-bib-0003){ref-type="ref"}, [4](#tca12301-bib-0004){ref-type="ref"}, [5](#tca12301-bib-0005){ref-type="ref"}, [6](#tca12301-bib-0006){ref-type="ref"} They can also provide sufficient specimens for molecular testing, which is essential in the era of personalized therapy.[7](#tca12301-bib-0007){ref-type="ref"}

The WANG MW‐319 TBNA needle (ConMed, Utica, NY, USA) is widely used and is the most commonly reported type of 19‐gauge TBNA needle (Fig [1](#tca12301-fig-0001){ref-type="fig"}a). We adopted the WANG MW‐319 TBNA needle for histologic diagnosis in June 2000. A new 19‐gauge eXcelon needle (Boston Scientific, Boston, MA, USA) was introduced in Taiwan in July 2012 (Fig [1](#tca12301-fig-0001){ref-type="fig"}b). The aim of this prospective study was to evaluate the performance of the 19‐gauge eXcelon needle and compare it with the MW‐319 needle.

![(a) The MW‐319 needle. (b) The 19‐gauge eXcelon needle. (c) Tips of the 21‐gauge NA‐2C‐1 needle, 19‐gauge eXcelon needle, and MW‐319 needle. (d) Longer needle bevel of the 19‐gauge eXcelon needle.](TCA-7-264-g001){#tca12301-fig-0001}

Materials and methods {#tca12301-sec-0002}
=====================

Patient enrollment criteria for TBNA at the Sun Yat‐Sen Cancer Center, a 200 bed hospital, included the evaluation of unknown hilar and/or mediastinal lesions, the evaluation of lymph nodes (LNs) with a short axis diameter larger than 1 cm, or smaller positive LNs, on postitron emission tomography‐computed tomography (PET/CT), which have a clinically relevant impact on cancer management.[8](#tca12301-bib-0008){ref-type="ref"} The indications were evaluated by a multidisciplinary group including radiologists, nuclear medicine physicians, thoracic surgeons, medical oncologists, and pulmonologists, after review of the images. Nineteen gauge needles were used when the hilar and/or mediastinal lesions were the solitary intrathoracic abnormality and the pathology was suspected to be of benign origin, for example, sarcoidosis, tuberculosis, or lymphoproliferative processes (e.g. lymphoma). All examinations were performed under conscious sedation and topical anesthesia by the same pulmonologist. The needle was advanced and inspected before the procedure. The specimens in the TBNA needles were flushed by air, and rapid on‐site cytological evaluation (ROSE) was performed. For quality assessment of a pathological sample, the presence of numerous lymphocytes or a definite pathologic diagnosis was necessary for a specimen to be considered adequate. Blood contamination was defined as blood occupying more than half of the low‐power fields (40×) examined on the most bloody slide. If a histologic specimen could not be obtained using the 19‐gauge needle on the first aspiration, a second TBNA was attempted. The number of needle passes was limited to four adequate aspirations by ROSE if a histologic specimen could still not be obtained.[9](#tca12301-bib-0009){ref-type="ref"} The histologic specimens were fixed in formalin, and cytologic specimens were smeared on glass slides and fixed in alcohol before being sent to the Department of Pathology. Both International Association for the Study of Lung Cancer (IASLC) nodal station and Wang TBNA staging systems were used to denote LN aspiration.[5](#tca12301-bib-0005){ref-type="ref"}, [10](#tca12301-bib-0010){ref-type="ref"}, [11](#tca12301-bib-0011){ref-type="ref"} The 19‐gauge eXcelon transbronchial needle was used between July 2012 and December 2012, and the results were compared with the historical control of TBNA using the MW‐319 needle in the antecedent 18 months from January 2011 to June 2012.

The eXcelon transbronchial needle is available in 19, 20, and 21 gauges. All needles have a clear Teflon catheter with a length of 130 cm and an outer diameter of 1.8 mm, with a needle length of 15 mm. The catheter is designed to be kink resistant and the needle is designed with an increased volume for specimen collection. It has a button lock system to minimize the risk of unintentional needle deployment or retraction. There is a fused hub and needle configuration to help prevent needle detachment, a vacuum lock syringe to maintain the vacuum during puncture, and an ergonomic handle, designed for single‐hand needle manipulation. In Taiwan, the price of a 19‐gauge eXcelon needle is the same as a MW‐319 needle (\$153 USD).

The institutional review board and the ethics committee of the Sun Yat‐Sen Cancer Center approved this study (No.20120522A). The study was conducted in accordance with the ethical principles stated in the 2000 Declaration of Helsinki. Written informed consent was obtained from all patients.

Statistical analysis {#tca12301-sec-0003}
--------------------

Data were expressed as numbers and percentages of cases or mean ± standard deviation, as appropriate. Diagnostic accuracy was calculated by the patient. Continuous variables were analyzed using the Student\'s *t*‐test, and categorical data were compared by Pearson χ^2^ test. All analyses were conducted with SAS version 8.02 (SAS Institute Inc., Cary, NC, USA), and a *P* value of less than 0.05 was considered to be statistically significant.

Results {#tca12301-sec-0004}
=======

The 19‐gauge eXcelon needle group included nine patients (4 women, 5 men), with a mean age of 48.3 years, and 15 LNs were aspirated. Sarcoidosis was diagnosed in four patients ( Fig [2](#tca12301-fig-0002){ref-type="fig"}a,b), lymphoma in one (Fig [2](#tca12301-fig-0002){ref-type="fig"}c,d), adenocarcinoma in one (Fig [3](#tca12301-fig-0003){ref-type="fig"}a,b), and Castleman\'s disease in one. A diagnosis could not be determined in two patients because of the lack of an adequate sample; one was diagnosed with spindle cell neoplasm by video‐assisted thoracic surgery (Fig [3](#tca12301-fig-0003){ref-type="fig"}c,d), and the other was diagnosed with benign lymphadenopathy which had been stable during a follow‐up of more than six months. The mean LN diameter was 23.3 ± 10.7 mm, and the mean number of needle passes was 2.7 ± 1.4. The diagnostic sensitivity and accuracy were 77.8% and 77.8%, respectively.

![(a) Enlarged sub‐subcarina lymph node from a 57‐year‐old woman. Transbronchial needle aspiration (TBNA) using the eXcelon needle was performed (inset). (b) Granulomatous inflammation was noted (hematoxylin and eosin stain; original ×100). (c) Enlarged posterior carina lymph node from a 74‐year‐old man. TBNA using the eXcelon needle was performed (inset). (d) Follicular lymphoma grade 2 was noted (hematoxylin and eosin stain; original ×100).](TCA-7-264-g002){#tca12301-fig-0002}

![(a) Enlarged posterior carina lymph node from a 63‐year‐old man. Transbronchial needle aspiration (TBNA) using the eXcelon needle was performed (inset). (b) Carcinoma with significant blood and benign respiratory epithelia in the background were noted (hematoxylin and eosin stain; original ×100). (c) Enlarged right paratracheal lymph node from a 63‐year‐old man. TBNA using the eXcelon needle was performed (inset). (d) Significant blood contamination and ciliated epithelia were noted (hematoxylin and eosin stain; original ×400).](TCA-7-264-g003){#tca12301-fig-0003}

The MW‐319 needle was used in 12 patients, (4 women, 8 men) with a mean age of 53.1 years, and 18 LNs were aspirated. Sarcoidosis was diagnosed in three patients, non‐small cell lung cancer in three, colorectal cancer metastasis in one, and mediastinal tuberculosis in one. One patient was regarded as having a benign lymphadenopathy, with the LN remaining stable for more than six months. The specimens were inadequate for diagnosis in three patients with sarcoidosis, thymic carcinoma, and lung adenocarcinoma metastasis. The mean LN diameter was 21.3 ± 5.7 mm, and the mean number of needle passes was 2.2 ± 0.4. The diagnostic sensitivity and accuracy were 72.7% and 75.0%, respectively.

The characteristics of the patients and lesions were similar between the two groups (Table [1](#tca12301-tbl-0001){ref-type="table-wrap"}). There was no significant difference in the diagnostic yield; however, the MW‐319 needle group had fewer needle passes for smaller LNs, although the difference did not reach statistical significance. No technical complication occurred. There were neither major clinical complications leading to premature termination of the procedure nor post‐procedural pneumothorax or infection in either group. Although blood loss was less than 50 mL in both groups, there was brisk bleeding on withdrawal of the needle, more blood mixed with secretion suctioned during TBNA (mean, 10.8 vs. 7.2 mL; *P* value \< 0.001) according to the nursing procedural records, and more frequent blood contamination (4/9, 44.4% vs. 2/12, 16.7%; *P* value = 0.331) in the eXcelon needle group (Fig [3](#tca12301-fig-0003){ref-type="fig"}b,d).

###### 

Comparison between TBNA using 19‐gauge eXcelon and MW‐319 needles

  Variable                                                 eXcelon (n = 9)   MW‐319 (n = 12)   *P* value
  -------------------------------------------------------- ----------------- ----------------- -----------
  Age, years                                               48.3 ± 18.7       53.1 ± 20.1       0.806
  Gender F/M                                               4/5               4/8               0.690
  Final diagnosis                                                                              0.714
  Malignant                                                4                 5                 
  Benign disease                                           5                 7                 
  Lymph node location                                      15                18                0.431
  4R                                                                                           
  anterior carina                                          2                 5                 
  right paratracheal                                       4                 6                 
  right main bronchus                                      0                 2                 
  4L                                                                                           
  left paratracheal                                        0                 1                 
  7                                                                                            
  posterior carina                                         2                 2                 
  subcarina                                                1                 1                 
  sub‐subcarina                                            1                 0                 
  11R                                                                                          
  right upper hilar                                        3                 1                 
  11L                                                                                          
  left hilar                                               2                 0                 
  Lymph node size, mm                                      23.3 ± 10.7       21.3 ± 5.7        0.458
  Needle passes                                            2.7 ± 1.4         2.2 ± 0.4         0.254
  TBNA results                                                                                 0.700
  True positive                                            7                 8                 
  True negative                                            0                 1                 
  False negative[\*](#tca12301-note-0002){ref-type="fn"}   2                 3                 
  Sensitivity                                              7/9 (77.8%)       8/11 (72.7%)      
  Accuracy                                                 7/9 (77.8%)       9/12 (75.0%)      

\*Including inadequate for diagnosis. TBNA, transbronchial needle aspiration.
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Discussion {#tca12301-sec-0005}
==========

Using a 19‐gauge TBNA needle to obtain larger specimens is essential in certain circumstances requiring histologic diagnosis or molecular testing. Both 19‐gauge and 21‐gauge eXcelon needles have been evaluated in a few studies.[12](#tca12301-bib-0012){ref-type="ref"}, [13](#tca12301-bib-0013){ref-type="ref"}, [14](#tca12301-bib-0014){ref-type="ref"}, [15](#tca12301-bib-0015){ref-type="ref"} However, to the best of our knowledge, this is the first study to make a direct comparison between the 19‐gauge eXcelon and MW‐319 needles.

Between September 1999 and March 2013, TBNA using a 21‐gauge NA‐2C‐1 (Olympus, Tokyo, Japan) (Fig [1](#tca12301-fig-0001){ref-type="fig"}c) or 19‐gauge needle was performed in 275 patients with 440 LNs aspirated at our hospital.[16](#tca12301-bib-0016){ref-type="ref"} The mean short‐axis diameter of the LNs aspirated was 14.4 ± 3.0 mm, and the mean number of needle passes to successfully aspirate the LNs or to make a diagnosis of cancer was 2.4 ± 0.6. The diagnostic sensitivity and accuracy were 73.2% and 76.7%, respectively. The plateau of TBNA diagnostic accuracy was reached after the first two years of a learning curve.[17](#tca12301-bib-0017){ref-type="ref"} Based on the same proficiency level, we made a head‐to‐head comparison between the 19‐gauge eXcelon and MW‐319 needle groups. The diagnostic sensitivity or accuracy of 19‐gauge eXcelon was comparable to the MW‐319 needle, despite the fact that the LN stations targeted were different, with more 4R and 7 stations in the MW‐319 needle group (88.9% vs. 66.7%), which assumed higher yields as more prevalent and easily accessible from prior experience.[11](#tca12301-bib-0011){ref-type="ref"}, [16](#tca12301-bib-0016){ref-type="ref"} The cost of the 19‐gauge eXcelon needle was also comparable to MW‐319 needle. The MW‐319 needle has an inner 21‐gauge needle (Fig [1](#tca12301-fig-0001){ref-type="fig"}c) to prevent plugging by a piece of normal bronchial mucosa, which possibly contributed to a more adequate specimen and required fewer needle passes, albeit non‐significantly. The 19‐gauge eXcelon needle had the advantage of easy penetration; however, brisk bleeding on withdrawal of the needle and more blood contamination on the slides were also noted, which could be attributed to the longer needle bevel of the 19‐gauge eXcelon needle (Fig [1](#tca12301-fig-0001){ref-type="fig"}d). A pathologist\'s opinion should be sought if contamination by blood leads to an inability to interpret slides.

On the other hand, the MW‐319 needle requires continuous application of negative suction by an assistant, whereas the eXcelon needle has a vacuum syringe attached. Doctors and assistants views upon the ease of application should be sought. Compared with the simplicity of the eXcelon needle with the safety lock, core expulsion of the MW‐319 needle could occur if the assistant is not familiar with the process.

Through education and experience, conventional TBNA has become a safe and accurate procedure for hilar‐mediastinal diagnosis and staging at our institute.[8](#tca12301-bib-0008){ref-type="ref"}, [16](#tca12301-bib-0016){ref-type="ref"}, [17](#tca12301-bib-0017){ref-type="ref"} Endobronchial ultrasonography‐guided (EBUS)‐TBNA using real‐time imaging is helpful to confirm that the needle is within the lesion, and it has been reported to result in a higher diagnostic yield.[18](#tca12301-bib-0018){ref-type="ref"}, [19](#tca12301-bib-0019){ref-type="ref"}, [20](#tca12301-bib-0020){ref-type="ref"} At present, the maximum needle size for EBUS‐TBNA is 21‐gauge (Olympus, NA‐201SX‐4021).[21](#tca12301-bib-0021){ref-type="ref"}, [22](#tca12301-bib-0022){ref-type="ref"} Nakajima *et al*. reported histological evaluation using "core material" was even possible using the 22‐gauge needle for EBUS‐TBNA.[23](#tca12301-bib-0023){ref-type="ref"} Further studies are needed to examine whether there are differences in obtaining adequate tissue for histology, immunohistochemistry, molecular analysis, and gene typing between 19, 21, and 22 gauge TBNA needles, and the continuous development of a 19‐gauge or larger EBUS‐TBNA needle is necessary.[9](#tca12301-bib-0009){ref-type="ref"}

Procedures by the same operator at the same institution exclude bias as a result of technical differences in LN sampling and specimen processing. However, the control group is a historical comparison group. The procedure was not performed on the same patient using both needles or in two parallel groups to assure random distribution of the two different needles. Unfamiliarity of the 19 gauge eXcelon needle may bias the results. However, operator and assistant skill, and the pathologist\'s comfort with needle specimens all may have improved over the course of the study period, which would bias the results in favor of the eXcelon needle. The small sample size and different disease demographics between the two groups are also limitations of this study. In addition to needle size, the ability to obtain a suitable histologic specimen also depends on the characteristics of the lesion.[24](#tca12301-bib-0024){ref-type="ref"} Taking into account the study limitations, the 19‐gauge eXcelon needle is as safe and effective as the MW‐319 needle, according to preliminary results. Larger comparative studies are required.
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